Current and upcoming treatments for Behçet disease;Traitements actuels et perspectives thérapeutiques dans la maladie de Behçet

Presse Medicale

Volumn 37, Issue 2 PART 2, 2008, Pages

  Houman, Mohamed Habib ^a   Smiti Khanfir, Monia ^a   Hamzaoui, Kamel ^b  

^a Service de médecine interne

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CD52 ANTIGEN; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DIPYRIDAMOLE; HEPARIN; INFLIXIMAB; LIDOCAINE; MACAMPATH; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; SUCRALFATE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; CANCER ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANEURYSM; BEHCET DISEASE; BONE MARROW TRANSPLANTATION; EYE INFLAMMATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; NEUROLOGIC DISEASE; NEUROPATHY; PROGNOSIS; RECURRENT DISEASE; RETINOPATHY; SHORT SURVEY; UVEITIS; VASCULITIS; VEIN THROMBOSIS; DRUG ANTAGONISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIVIRAL AGENTS; BEHCET SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41949137336     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.03.037     Document Type: Short Survey

References (92)

1. International Study Group for Behçet's Disease. criteria for diagnostic of Behçet's disease. Lancet 335 (1990) 1078-1080
2. Dilsen N. History and development of Behçet's disease. Rev Rhum 63 (1996) 512-519 [Engl Ed]
3. Zouboulis C.C. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris) 150 (1999) 488-498
4. Direskeneli H. Behçet's disease : infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60 (2001) 996-1002
5. Hamzaoui K., Ayed K., Slim A., Hamza M., and Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease. Clin Exp Immunol 79 (1990) 28-34
6. Ohno S., Ohguchi M., Hirose S., Matsuda H., Wakisaka A., and Aizawa M. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 100 (1982) 1455-1458
7. Ben Ahmed M., Houman H., Miled M., Dellagi K., and Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum 50 (2004) 2291-2295
8. Houman M.H., Hamzaoui A., Smiti-Khanfir M., Ben Ghorbel I., Fki M., and Hamzaoui K. Abnormal expression of chemokine receptors in Behçet's disease : Relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 23 (2004) 267-273
9. Yurdakul S., Mat C., Tuzun Y., Ozyazgan Y., Hamuryudan V., Uysal O., et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 44 (2001) 2686-2692
10. Vignes S., Vidailhet M., Dormont D., Soulié J., and Wechsler B. Présentation pseudotumorale de neuro-Behçet : rôle de l'arrêt de la colchicine?. Rev Med Int. 19 (1998) 55-59
11. Sharquie K.E., Najim R.A., and Abdugharif A.R. Dapsone in Behçet's disease a double-blind, placebo-controlled study. J Dermatol 29 (2002) 267-279
12. Yazici H., Pazarli H., Barnes C.G., Tuzun Y., Ozyazgan Y., Silman A., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322 (1990) 281-285
13. Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome : a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128 (1998) 443-450
14. Calguneri M., Ertenli I., Kiraz S., Erman M., and Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 192 (1996) 125-128
15. Mumcu G., Ergun T., Elbir Y., Eksioglu-Demiralp E., Yavuz S., Atalay T., et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 34 (2005) 13-16
16. Yasui K., Ohta K., Kobayashi M., Aizawa T., and Komiyama A. Successfull treatment of Behçet's disease with pentoxxifylline. Ann Intern Med 124 (1996) 891-893
17. Hamuryudan V., Ozyazgan Y., Hizli N., Mat C., Yurdakul S., Tuzun Y., et al. Azathioprine in Behçet's syndrome : effects on long-term prognosis. Arthritis Rheum 40 (1997) 769-774
18. Mudun B.A., Ergen A., Ipcioglu S.U., Burumcek E.Y., Durlu Y., and Arslan M.O. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 9 (2001) 219-229
19. Özyazgan Y., Yurdakul S., Yazici H., Tuzun B., Iscimen A., Tuzun Y., et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76 (1992) 241-243
20. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., and Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1 (1989) 1093-1096
21. Sullu Y., Oge I., Erkan D., Ariturk N., and Mohajeri F. Cyclosporine A therapy in severe uveitis of Behçet's disease. Acta Ophtalmol Scand. 76 (1998) 96-99
22. Davatchi F., Shahram F., Chams H., Akbarian N., Nadji A., Gharibdoost C., et al. Methotrexate for ocular lesions of Behçet's disease. Cohort study on 262 patients (abstr). Arthritis Rheum 41 suppl (1998) S356
23. Yazici H., and Ozyazgan Y. Medical management of Behçet's syndrome. Dev Ophthalmol 31 (1999) 118-131
24. Houman M.H., Bchir S., Ben Ghorbel I., Ben Ahmed M., Lamloum M., and Miled M. Les manifestations neurologiques de la maladie de Behçet. Rev Med Int. 23 (2002) 592-606
25. Serdarglu P. Behçet's disease and the nervous system. J Neurol 245 (1998) 197-205
26. Siva A., and Fresko I. Behçet's Disease. Curr Treat Options Neurol 2 (2000) 435-448
27. Kikuchi H., Aramaki K., and Hirohata S. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol 528 (2003) 575-578
28. Kotter I., Gunaydin I., Batra M., Vonthein R., Stubiger N., Fierlbeck G., et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol (2005) 1-5
29. Kotake S., Higashi K., Yoshikawa K., Sasamoto Y., Okamoto T., and Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 106 (1999) 586-589
30. Houman M.H., Ben Ghorbel I., Khiari Ben Salah I., Lamloum M., Ben Ahmed M., and Miled M. Deep vein thrombosis in Behçet's disease. Clin Exp Rheumatol 19 (2001) 48-50
31. Houman M.H., Ksontini I., Ben Ghorbel I., Lamloum M., and Miled M. Association of right heart thromboses, endomyocardial fibrosis and pulmonary artery aneurysm in Behçet's disease. Eur J Int Med. 13 (2002) 455-456
32. Calamia K.T., Schirmer M., and Melikoglu M. Major vessel involvement in Behçet disease. Curr Opin Rheumatol 17 (2005) 1-8
33. Koç Y., Güllü I., Akpek G., Akpolat T., Kansu E., Kiraz S., et al. Vascular involvement in BD. J Rheumatol 19 (1992) 402-410
34. Espinosa G., Cervera R., Reverter J.C., Ássies D.T., Font J., and Ingelmo M. Vascular Involvement in Behçet's Disease. Isr Med Assoc J 4 (2002) 614-616
35. Evereklioglu C. Current Concepts in the Etiology and Treatment of Behçet Disease. Surv Ophthalmol 50 (2005) 297-350
36. O'Duffy J.D. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 16 (1990) 423-431
37. Dincer I., Dandachi R., Atmaca Y., Erol C., Caglar N., and Oral D. A recurrent right atrial thrombus in a patient with Behçet's disease. Echocardiography 18 (2001) 15-18
38. Ben Ghorbel I., Ibn Elhadj Z., Khanfir M., Braham A., Fekih M., Drissa H., et al. Tromboses intracardiques au cours de la maladie de Behçet. J Mal Vasc 29 (2004) 159-161
39. Nitecki S.S., Ofer A., Karram T., Schwartz H., Engel A., and Hoffman A. Abdominal aortic aneurysm in Behçet's disease : new treatment options for an old and challenging problem. Isr Med Assoc J 6 (2004) 152-155
40. Robenshtok E., and Krause I. Arterial involvement in Behçet's disease-the search for new treatment strategies. Isr Med Assoc J 6 (2004) 162-163
41. Bautista-Hernandez V., Gutierrez F., Capel A., Garcia-Puente J., Arribas J.M., Ray V.G., et al. Endovascular repair of concomitant celiac trunk and abdominal aortic aneurysms in a patient with Behçet's disease. J Endovasc Ther 11 (2004) 222-225
42. Le Thi Huong D., Wechsler B., Papo T., Piette J.C., Bletry O., Vitoux J.M., et al. Arterial lesions in Behçet's disease : a study in 25 patients. J Rheumatol 22 (1995) 2103-2113
43. Zouboulis C.C., and Orfanos C.E. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134 (1998) 1010-1016
44. Kotter I., Zierhut M., Eckstein A., Vonthein R., Ness T., Gunaydin I., et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87 (2003) 423-431
45. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., et al. Interferon alfa-2a in the treatment of Behçet disease : a randomized placebo controlled and double-blind study. Arch Dermatol 138 (2002) 467-471
46. Wechsler B., Bodaghi B., Huong D.L., Fardeau C., Amoura Z., Cassoux N., et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8 (2000) 293-301
47. Wechsler B., and Du-Boutin L.T. Interferons and Behçet's disease. Rev Med Interne 23 Suppl 4 (2002) 495s-499s
48. Seyahi E., Ugurlu S., Ozyazgan Y., Melikoglu M., Fresko I., Hamuryudan V., et al. Arthritis Rheum 52 (2005) S647 [Abstr]
49. Kötter I., Günaydin I., Zierhut M., and Stübiger N. The Use of Interferon α in Behçet Disease : Review of the Literature. Semin Arthritis Rheum 33 (2004) 320-335
50. Kadayifcilar S., Boyacioglu S., Kart H., Gursoy M., and Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 13 (1999) 241-246
51. Budak-Alpdogan T., Demircay Z., Alpdogan O., Direskeneli H., Ergün T., Bayik M., et al. Behçet's disease in patients with chronic myelogenous leukemia : Possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms. Ann Hematol 74 (1997) 45-48
52. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 19 (2001) S6-S12
53. Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., Gomez Vidal M.A., Collantes Estevez E., Ramirez Chamond R., et al. Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis. Ophthalmic Res 33 (2001) 251-255
54. Ando K., Fujino Y., Hijikata K., Izawa Y., and Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol 43 (1999) 312-317
55. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., et al. Short-Term Trial of Etanercept in Behçet's Disease : A Double Blind, Placebo Controlled Study. J Rheumatol 32 (2005) 98-105
56. Melikoglu M., Ozyazgan Y., Fresko I., Mat C., Yurdakul S., Hamuryudan V., et al. The response of treatment resistant uveitis in Behçet's syndrome [BS] to a TNF-a blocker, etanercept : an open study. Arthritis Rheum 46 (2002) S181
57. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., and Markomichelakis N.N. Effect of infliximab on sight threatening panuveitis in Behçet's disease. Lancet 358 (2001) 295-296
58. Saulsburg F.T., and Mann J.A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 49 (2003) 599-600
59. Hassard P.V., Binder S.W., Nelson V., and Vasiliauskas F.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease : a case report. Gastroenterology 120 (2001) 993
60. Rozenbaum M., Rosner I., and Portnoy E. Remission of Behçet's syndrome with TNF alpha blocking treatment. Ann Rheum Dis 61 (2002) 283-284
61. Joesph A., Raj D., Dua H.S., Powell P.T., Lawson P.C., Powell R.J., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
62. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., et al. A prospective trial of Infliximab therapy for refractory uveitis. Arch Ophtalmol (Paris) 123 (2005) 903-912
63. Gulli S., Arrigo C., Bocchino L., Morgan T.E., Sangari D., Castagna E., et al. Remission of Behçet's desease with anti-tumor necrosis factor monoclonal antibody therapy : a case report. BMC Musculoskelet Disord 4 (2003) 19
64. Arayssi T., Hamra R., Awwad S., Kazma I., Homaidan F., Uthman I., et al. Treatment of refractory vitritis in Behçet disease with infliximab. Arthritis Rheum 46 (2002) S181
65. Sfikakis P.P. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 suppl 2 (2002) ii51-ii53
66. Robertson L.P., and Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatol 40 (2001) 473-474 [Oxford]
67. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140 (2004) 404-406
68. Wechsler B., Sablé-Fourtassou R., Boghadi B., Houong D.L.T., Cassoux N., Badelon I., et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 22 suppl. 34 (2004) S14-S16
69. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1362-1368
70. Lanthier N., Parc C., Scavennec R., Dhôte R., Brézin A.P., and Guillevin L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow-up in four patients. Presse Med 34 (2005) 916-918
71. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 52 (2005) 2478-2484
72. Lowder CJ, Galor A, Perez VL. Differential effectiveness of etanercept and infliximab in ocular inflammation. Poster 351 presented at the 2005 Annual Meeting of the Arvo (the Association for Research in Vision and Ophthalmology). Disponible sur : www.arvo.org.
73. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H.C., Cassoux1 N., Le Thi Huong D., et al. Therapeutic use of infliximab in sight threatening uveitis : retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64 (2005) 962-964
74. Giansanti F., Barbera M.L., Virgili G., Pieri B., Emmi L., and Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 14 (2004) 445-448
75. Sayarlioglu M., Cinal A., Topcu N., and Demirok A. Effect of infliximab on refractory uveitis in Behçet's disease. Ann Pharmacother 38 (2004) 901-902
76. Kram M.T., May L.D., Goodman S., and Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody [infliximab] therapy: report of a case. Dis Colon Rectum 46 (2003) 118-121
77. Haugeberg G., Velken M., and Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 63 (2004) 744-745
78. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., and Yiannopoulos G. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease. Clin Exp Rheumatol 21 (2003) S57-S58
79. Sarwar H., Mcgrath Jr. H., and Espinoza L.R. Successful Treatment of Long-standing Neuro-Behçet's Disease with Infliximab. J Rheumatol 32 (2005) 181-183
80. Behrens F., Zollner T., Moeller B., Kaltwasser J.P., Kaufmann R., and Ochsendorf F.R. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease. Adv Exp Med Biol 528 (2003) 561-562
81. Estrach C., Mpofu S., and Moots R.J. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatol 41 (2002) 1213-1214 [Oxford]
82. Van Deventer S.J.H. Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121 (2001) 1242-1245
83. Blonski W., and Lichtenstein G.R. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 22 (2006) 30-43
84. De Smet M.D., Bitar G., Mainigi S., and Nussenblatt R.B. Humn S-antigen determinant recognition in uveitis. Invest Ophthalmol Vis Sci 42 (2001) 3233-3238
85. Stanford M., Whittall T., Bergmeier L.A., Lindblad M., Lundin S., Shinnick T., et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behçet's disease. Clin Exp Immunol 137 (2004) 201-208
86. Breitbart A., and Ho A.D. Autologous Hematopoietic Stem-Cell Transplantation for Behçet's Disease with Pulmonary Involvement. N Engl J Med 344 (2004) 69
87. Rossi G., Moretta A., and Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behçet disease. Blood 103 (2004) 748-750
88. Lockwood C.M., Hale G., Waldman H., and Jayne D.R. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42 (2003) 1539-1544
89. Chambers J.C., Haskard D.O., and Kooner J.S. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 37 (2001) 517-520
90. Kokcam I., and Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behçet's disease. Clin Biochem 35 (2002) 633-639
91. Sharquie K.E., Najim R.A., Al-Dori W.S., and Al-Hayani R.K. Oral zinc sulfate in the treatment of Behçet's disease: a double blind cross-over study. J Dermatol 33 (2006) 541-546
92. Saglam K., Serce A.F., Yilmaz M.I., Bulucu F., Aydin A., Akay C., et al. Trace elements and antioxidant enzymes in Behçet's disease. Rheumatol Int 22 (2002) 93-96